Posts Tagged ec145
Endocyte’s EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum Resistant Ovarian Cancer
- Data Presented at 2011 ASCO Annual Meeting - 260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup - Plan to File for Conditional Approval in Europe - Initiated Phase 3 PROCEED Trial WEST LAF...
Endocyte to Present Final PRECEDENT Study Data on Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 at ASCO Annual Meeting
WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the final progression free survival (PFS) data ...